University of Hertfordshire

Standard

Harvard

APA

Vancouver

Author

Bibtex

@misc{9401ecff535a4275a4eb62698c98a94f,
title = "Arylalkylpiperazines for use as neuroprotective agents: Arlyalkylpiperazines and neuroprotection",
abstract = "A compound of the general formula A or a or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 is selected from the group consisting of: C1-C12-alkyl, C3-C12-cycloalkyl, C6- C10-aryl, and C5-C7-heteroaryl; each optionally substituted with halogen, hydroxyl, OCOR3, amino, C1-C6-alkylamino, C1-C6-dialkylamino, C1C6- (halo)alkyl, C1C6-(halo)- alkoxy and/or COOR3; R2 is selected from the group consisting of: C6-C10-aryl and C5-C7-heteroaryl; each optionally substituted with halogen, hydroxyl, OCOR3 amino, C1C6- alkylamino, CrC6-dialkyl- amino, C1-C6-(halo)alkyl, C1C6-(halo)alkoxy and/or COOR3; R3 is independently at each occurrence selected from the group consisting of hydrogen and C1-C2-alkyl; and n is an integer from 1 to 10 inclusive.",
keywords = "NEURODEGENERATIVE DISEASE, arylalkylpiperazines, dopamine D-2 receptors, serotonin 5-HT1A receptors, OXIDATIVE STRESS",
author = "Mahmoud Iravani",
year = "2016",
month = apr,
day = "7",
language = "English",
type = "Patent",
note = "WO2016051155 A1",

}

RIS

TY - PAT

T1 - Arylalkylpiperazines for use as neuroprotective agents

T2 - Arlyalkylpiperazines and neuroprotection

AU - Iravani, Mahmoud

PY - 2016/4/7

Y1 - 2016/4/7

N2 - A compound of the general formula A or a or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 is selected from the group consisting of: C1-C12-alkyl, C3-C12-cycloalkyl, C6- C10-aryl, and C5-C7-heteroaryl; each optionally substituted with halogen, hydroxyl, OCOR3, amino, C1-C6-alkylamino, C1-C6-dialkylamino, C1C6- (halo)alkyl, C1C6-(halo)- alkoxy and/or COOR3; R2 is selected from the group consisting of: C6-C10-aryl and C5-C7-heteroaryl; each optionally substituted with halogen, hydroxyl, OCOR3 amino, C1C6- alkylamino, CrC6-dialkyl- amino, C1-C6-(halo)alkyl, C1C6-(halo)alkoxy and/or COOR3; R3 is independently at each occurrence selected from the group consisting of hydrogen and C1-C2-alkyl; and n is an integer from 1 to 10 inclusive.

AB - A compound of the general formula A or a or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 is selected from the group consisting of: C1-C12-alkyl, C3-C12-cycloalkyl, C6- C10-aryl, and C5-C7-heteroaryl; each optionally substituted with halogen, hydroxyl, OCOR3, amino, C1-C6-alkylamino, C1-C6-dialkylamino, C1C6- (halo)alkyl, C1C6-(halo)- alkoxy and/or COOR3; R2 is selected from the group consisting of: C6-C10-aryl and C5-C7-heteroaryl; each optionally substituted with halogen, hydroxyl, OCOR3 amino, C1C6- alkylamino, CrC6-dialkyl- amino, C1-C6-(halo)alkyl, C1C6-(halo)alkoxy and/or COOR3; R3 is independently at each occurrence selected from the group consisting of hydrogen and C1-C2-alkyl; and n is an integer from 1 to 10 inclusive.

KW - NEURODEGENERATIVE DISEASE

KW - arylalkylpiperazines

KW - dopamine D-2 receptors

KW - serotonin 5-HT1A receptors

KW - OXIDATIVE STRESS

UR - http://www.google.com/patents/WO2016051155A1?cl=en

UR - https://www.ipo.gov.uk/p-ipsum/Case/PublicationNumber/GB2530598

UR - https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016051155

M3 - Patent

M1 - WO2016051155 A1

ER -